Today: 9 June 2026
Browse Category

NYSE:BSX 16 January 2026 - 31 May 2026

Boston Scientific Drops 16%. Next Up: Monday’s Watchman Reaction

Boston Scientific Drops 16%. Next Up: Monday’s Watchman Reaction

Boston Scientific shares plunged 16.4% last week, closing at $48.31 on May 29 after CEO Michael Mahoney flagged “declining usage” of the Watchman heart implant and forecast flat growth through Q3. Wells Fargo downgraded the stock, slashing its target to $55. Friday’s volume nearly doubled the 50-day average as rivals Abbott and Medtronic ramped up competition. A $2 billion buyback is underway, with results next due July 29.
31 May 2026
·
Boston Scientific Hits Two-Year Low After Watchman Device Warning

Boston Scientific Hits Two-Year Low After Watchman Device Warning

Boston Scientific shares fell about 10% Wednesday after CEO Mike Mahoney warned of weaker demand for its Watchman heart implant. The stock hit $50.60, its lowest in over two years. Mahoney said Watchman sales likely won’t grow from the first to third quarter, citing a shift to combined procedures. The company maintained its full-year organic revenue growth forecast of 6.5% to 8%.
27 May 2026
··
US Stock Market Today: Nasdaq Leads Wall Street Rally as Iran Ceasefire Relief Meets Earnings Momentum

US Stock Market Today: Nasdaq Leads Wall Street Rally as Iran Ceasefire Relief Meets Earnings Momentum

The Nasdaq rose 1.29% as technology and chip stocks led gains after President Trump extended the Iran ceasefire. GE Vernova, Boeing, and Boston Scientific advanced following earnings reports. Oil hovered near $100, with fresh ship seizures in the Strait of Hormuz highlighting ongoing risks. At 11:25 a.m. ET, the Dow was up 381 points, the S&P 500 gained 61 points, and the Nasdaq climbed 314 points.
22 April 2026
······
Boston Scientific stock price slips again after earnings shock as BSX investors eye heart-rhythm sales

Boston Scientific stock price slips again after earnings shock as BSX investors eye heart-rhythm sales

Boston Scientific shares closed down 1.8% at $76.27 Friday, near post-earnings lows after a 17% plunge Wednesday on weak electrophysiology sales and a softer 2026 outlook. Trading volume reached 34.9 million shares. The stock lagged peers as the S&P 500 rose about 2%. Investors are watching early-quarter demand signals ahead of the next earnings update in late April.
7 February 2026
··
Boston Scientific stock rebounds after earnings shock as analysts cut targets on EP worries

Boston Scientific stock rebounds after earnings shock as analysts cut targets on EP worries

Boston Scientific shares rose 2.8% to $77.64 in Thursday’s after-hours trading, rebounding after a record 17% plunge Wednesday on weak Q4 electrophysiology and Watchman sales. Citi and Wells Fargo lowered price targets but kept positive ratings. Fourth-quarter net sales reached $5.29 billion, with adjusted EPS of $0.80. The company expects 2026 adjusted EPS of $3.43–$3.49.
6 February 2026
··
Boston Scientific stock tries to steady after an 18% earnings drop put EP business on edge

Boston Scientific stock tries to steady after an 18% earnings drop put EP business on edge

Boston Scientific shares rose about 1% in Thursday premarket trading after plunging 17.6% Wednesday on weak electrophysiology sales and a softer 2026 outlook. Q4 electrophysiology revenue missed analyst estimates, and U.S. Watchman sales fell short. The stock traded near $76.30 after closing at $75.50. CEO Michael Mahoney said Q4 results beat internal targets but warned of challenges in the first quarter.
5 February 2026
··
Boston Scientific (BSX) stock dives on electrophysiology sales miss — what to watch after the bell

Boston Scientific (BSX) stock dives on electrophysiology sales miss — what to watch after the bell

Boston Scientific shares fell nearly 18% in after-hours trading Wednesday after the company reported disappointing electrophysiology sales and lowered its 2026 growth outlook. U.S. demand for the Watchman implant also missed expectations. The company guided first-quarter adjusted EPS to $0.78–$0.80 and organic revenue growth of 8.5%–10%. Analysts are watching for further estimate cuts and commentary on heart-rhythm procedure trends.
4 February 2026
·
Boston Scientific stock price skids as key heart-rhythm sales miss jolts BSX

Boston Scientific stock price skids as key heart-rhythm sales miss jolts BSX

Boston Scientific shares fell 15% to $77.83 after quarterly electrophysiology sales missed Wall Street estimates, with Q4 revenue in that segment at $890 million versus a $933 million consensus. Analysts flagged fresh doubts about growth in electrophysiology and Watchman devices. The stock’s drop marked its sharpest one-day decline in over 25 years. Investors await Watchman “CHAMPION” trial data at the ACC.26 meeting in March.
4 February 2026
·
Boston Scientific stock slips today: what to know before earnings and key Watchman trial data

Boston Scientific stock slips today: what to know before earnings and key Watchman trial data

Boston Scientific (BSX.N) slipped 0.7% to $91.20 in Tuesday afternoon trading, with about 10.4 million shares exchanged. CEO Michael F. Mahoney filed to potentially sell up to 160,901 shares valued at $15 million. The company reports fourth-quarter earnings Wednesday morning. Investors await late-March CHAMPION-AF trial results for the Watchman device.
3 February 2026
··
Boston Scientific stock price drops today: BSX slides as investors size up Feb. 4 earnings, Watchman trial date

Boston Scientific stock price drops today: BSX slides as investors size up Feb. 4 earnings, Watchman trial date

Boston Scientific shares fell 1.6% to $92.01 Monday, lagging sector peers as the S&P 500 rose. Investors are watching for the company’s Feb. 4 earnings call and the March 28 release of CHAMPION-AF trial results for its Watchman device. TD Cowen maintained a buy rating, citing potential upside if the trial data proves positive.
2 February 2026
··
Boston Scientific stock snaps a 4-day run — what to watch before Feb. 4 earnings

Boston Scientific stock snaps a 4-day run — what to watch before Feb. 4 earnings

Boston Scientific shares fell 1.6% to $92.33 Thursday, ending a four-day rally on heavy volume after the company completed its acquisition of Nalu Medical. The stock underperformed sector peers as investors awaited fourth-quarter results due Feb. 4 and looked for updates on recent deal activity, including the $14.5 billion Penumbra purchase.
30 January 2026
······
ISRG stock slips after FDA clears da Vinci 5 for heart procedures; TD Cowen starts at Buy

ISRG stock slips after FDA clears da Vinci 5 for heart procedures; TD Cowen starts at Buy

Intuitive Surgical shares fell 0.7% to $525.09 Tuesday after the FDA cleared its da Vinci 5 robot for select cardiac procedures. The S&P 500 ETF rose 0.5% and QQQ gained 0.9%. TD Cowen initiated coverage with a Buy rating and $660 target, citing potential for expanded hospital adoption. Intuitive forecasts 13–15% da Vinci procedure growth in 2026, with a 1.2% revenue hit from tariffs.
27 January 2026
····
Boston Scientific stock (BSX) climbs as heart-rhythm rivalry and deal risk stay in play

Boston Scientific stock (BSX) climbs as heart-rhythm rivalry and deal risk stay in play

Boston Scientific shares rose about 1% to $92.20 Friday, outperforming a weaker healthcare sector as investors focused on pulsed-field ablation for atrial fibrillation. The company’s $14.5 billion deal to buy Penumbra and its upcoming Feb. 4 earnings report are drawing scrutiny. Johnson & Johnson posted $24.6 billion in quarterly sales and gave 2026 guidance, while Medtronic and Abbott shares fell.
23 January 2026
Boston Scientific (BSX) stock falls again as traders digest $14.5 billion Penumbra buy

Boston Scientific (BSX) stock falls again as traders digest $14.5 billion Penumbra buy

Boston Scientific shares fell 1.8% to $88.44 Friday after its $14.5 billion deal to buy Penumbra, while Penumbra rose 0.3% to $351.62. Boston will fund most of the purchase with cash and new debt, expecting a $0.06–$0.08 hit to adjusted EPS in the first year. Penumbra shareholders can choose cash or Boston stock. Deal filings and Boston’s earnings call are set for February 4.
16 January 2026
··
Boston Scientific (BSX) stock drops after $14.5B Penumbra deal; FDA nod and earnings date ahead

Boston Scientific (BSX) stock drops after $14.5B Penumbra deal; FDA nod and earnings date ahead

Boston Scientific shares fell 4% Thursday after it announced a $14.5 billion cash-and-stock deal to buy Penumbra at $374 per share. Penumbra stock jumped 12% to $350.49. Boston Scientific warned of near-term EPS dilution and will fund about $11 billion in cash using debt and existing funds. Investors are watching for more details ahead of Boston Scientific’s earnings report on Feb. 4.
16 January 2026
···
1 2

Stock Market Today

  • Calculate How a 22% Social Security Cut in 2032 Could Affect Your Retirement
    June 9, 2026, 12:45 PM EDT. The latest Social Security Trustees report projects a 22% reduction in benefits by 2032. This potential cut could significantly impact retirees relying on these payments. Understanding the exact effect on your retirement income is crucial for planning. Experts suggest evaluating your financial strategy now to adjust for possible decreased Social Security revenue. Early preparation can help mitigate risks tied to this forecasted decline in benefits.

Latest articles

BlackBerry Shares Stall After QNX Push

BlackBerry Shares Slip Ahead of Results — What’s Moving BB Today

9 June 2026
BlackBerry’s U.S. shares plunged 8.5% to $8.50 as investors braced for the June 25 earnings report, with focus on whether the company can meet its bullish Q1 revenue forecast of $132–$140 million, well above analysts’ estimates, after QNX’s 20% revenue jump and $950 million royalty backlog last quarter.
Chip Selloff Trips Up Wall Street’s AI Rally

Chip Selloff Trips Up Wall Street’s AI Rally

9 June 2026
Nasdaq and S&P 500 tumbled midday, erasing early chip-stock gains as tech shares slid; Philadelphia Semiconductor Index dropped 2% after jumping 3%, with Broadcom, Micron, and Nvidia under pressure. Investors await key inflation data Wednesday and SpaceX’s massive IPO, both seen as catalysts for further volatility amid concerns that high valuations in AI and tech could face profit-taking if rate fears persist.
Nintendo and Sanrio Stocks Get New AI Boost

Nintendo and Sanrio Stocks Get New AI Boost

9 June 2026
Nintendo hikes Switch 2 prices in Japan and the US, citing higher memory costs and tariffs expected to add 100 billion yen to annual expenses; investors now question whether Japan’s top entertainment brands like Nintendo and Sanrio can maintain valuations as AI-driven capital shifts toward chips and automation, pressuring stock selection even as the Nikkei rebounds 2.17% after Monday’s sharp drop.
Costco Drops Kirkland Prices While Prepping New Florida Warehouse

Costco Drops Kirkland Prices While Prepping New Florida Warehouse

9 June 2026
Costco slashed prices on select Kirkland Signature products by up to $10 as part of its strategy to boost membership renewals, but shares barely moved, last at $973.50, down $1.25, after Q3 net sales rose 11.6% to $69.15 billion and net income hit $2.19 billion; management emphasized the cuts are strategic, not a chainwide rollback, amid slowing paid membership growth and ongoing competitive pressure.
Paranovus Stock Rockets 620% as $195 Million Share-Sale Filing Changes the Story

Paranovus Stock Rockets 620% as $195 Million Share-Sale Filing Changes the Story

9 June 2026
Paranovus Entertainment shares soared 620% to $6.76 after filing to potentially sell up to $195 million in new stock—an amount far exceeding its $7.14 million market cap—raising major dilution risks for investors as the company eyes acquisitions but warns that future share sales could pressure the stock price or threaten operations.
Go toTop